Abstract:Background: The prevalence of depression has been increasing worldwide in recent years, posing a heavy burden on patients and society. However, the diagnostic and therapeutic tools available for this disease are inadequate. Therefore, this research focused on the identification of potential biomarkers in the peripheral blood of patients with depression. Methods: The expression dataset GSE98793 of depression was provided by the Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/gds). Initially, differentially expressed genes (DEGs) were detected in GSE98793. Subsequently, the most relevant modules for depression were screened according to weighted gene co-expression network analysis (WGCNA). Finally, the identified DEGs were mapped to the WGCNA module genes to obtain the intersection genes. In addition, Gene Ontology (GO), Disease Ontology (DO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted on these genes. Moreover, biomarker screening was carried out by protein-protein interaction (PPI) network construction of intersection genes on the basis of various machine learning algorithms. Furthermore, the gene set enrichment analysis (GSEA), immune function analysis, transcription factor (TF) analysis, and the prediction of the regulatory mechanism were collectively performed on the identified biomarkers. In addition, we also estimated the clinical diagnostic ability of the obtained biomarkers, and performed Mfuzz expression pattern clustering and functional enrichment of the most potential biomarkers to explore their regulatory mechanisms. Finally, we also perform biomarker-related drug prediction. Results: Differential analysis was used for obtaining a total of 550 DEGs and WGCNA for obtaining 1,194 significant genes. Intersection analysis of the two yielded 140 intersection genes. Biological functional analysis indicated that these genes had a major role in inflammation-related bacterial infection pathways and cardiovascular diseases such as atherosclerosis. Subsequently, the genes S100A12, SERPINB2, TIGIT, GRB10, and LHFPL2 in peripheral serum were identified as depression biomarkers by using machine learning algorithms. Among them, S100A12 is the most valuable biomarker for clinical diagnosis. Finally, antidepressants, including disodium selenite and eplerenone, were predicted. Conclusion: The genes S100A12, TIGIT, SERPINB2, GRB10, and LHFPL2 in peripheral serum are viable diagnostic biomarkers for depression. and contribute to the diagnosis and prevention of depression in clinical practice.

Research progress in depression related biomarkers based on omics technology

Advances in biosensors for major depressive disorder diagnostic biomarkers

Research Progress of Biological Markers for Depression Based on Psychoradiology and Artificial Intelligence

Mapping the structure of depression biomarker research: A bibliometric analysis

Progress of Depression Mechanism Based on Omics Method

[Integration of basic and clinical researches to develop the biomarker of ‍depression]

Recent Progress in Biosensors for Depression Monitoring—Advancing Personalized Treatment

Screening and identification of key biomarkers of depression using bioinformatics

A cross talk on the role of contemporary biomarkers in depression

Energy Metabolism in Major Depressive Disorder: Recent Advances from Omics Technologies and Imaging.

Research progress of neuroendocrine immune inflammation in depression

Non-coding RNAs in Depression: Promising Diagnostic and Therapeutic Biomarkers

Metabolomics on depression: A comparison of clinical and animal research

Research Progress in Key Genes of Depression and Exercise Intervention Mechanism Based on the Bioinformatics Perspective

Review—Electrochemical Immunosensors for Depression Markers Detection: Development in Recent Years

Identification of Oxidative Stress-Related Biomarkers for Pain-Depression Comorbidity Based on Bioinformatics

Screening of potential biomarkers in peripheral blood of patients with depression based on weighted gene co-expression network analysis and machine learning algorithms

Early-diagnosis of major depressive disorder: From biomarkers to point-of-care testing

Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research

Identifying Key Biomarkers and Therapeutic Candidates for Post-Covid-19 Depression Through Integrated Omics and Bioinformatics Approaches

Omics in Schizophrenia: Current Progress and Future Directions of Antipsychotic Treatments